Cheryl Wei
Overview
Explore the profile of Cheryl Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailey C, Del Prato S, Wei C, Reyner D, Saraiva G
Diabetes Obes Metab
. 2019 Aug;
21(11):2564-2569.
PMID: 31364269
Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these...
2.
Sjostrand M, Wei C, Cook W, Johnsson K, Pollack P, Stahre C, et al.
Diabetes Ther
. 2017 Apr;
8(3):587-599.
PMID: 28432619
Introduction: This meta-analysis of data from 14 phase 2 and 3, double-blind, randomized, controlled 12- and 24-week studies (N = 4632) summarizes saxagliptin efficacy in patients with type 2 diabetes...
3.
Perl S, Cook W, Wei C, Ohman P, Hirshberg B
Clin Ther
. 2016 Nov;
38(12):2578-2588.
PMID: 27823868
Purpose: The management of hyperglycemia is challenging in older patients with type 2 diabetes owing to excess fragility and risk for adverse outcomes should hypoglycemia episodes occur. We evaluated baseline...
4.
Mosenzon O, Leibowitz G, Bhatt D, Cahn A, Hirshberg B, Wei C, et al.
Diabetes Care
. 2016 Nov;
40(1):69-76.
PMID: 27797925
Objective: Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy. Research Design And Methods: We studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to...
5.
Perl S, Cook W, Wei C, Iqbal N, Hirshberg B
Diabetes Ther
. 2016 Jul;
7(3):527-35.
PMID: 27402391
Introduction: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate...
6.
Mosenzon O, Wei C, Davidson J, Scirica B, Yanuv I, Rozenberg A, et al.
Diabetes Care
. 2015 Sep;
38(11):2142-50.
PMID: 26358285
Objective: Patients with type 2 diabetes have an increased risk of bone fractures, the predisposing factors for which are unknown. Treatment with thiazolidinediones (TZDs) further increases the incidence of osteoporotic...
7.
Birmingham B, Bujac S, Elsby R, Azumaya C, Wei C, Chen Y, et al.
Eur J Clin Pharmacol
. 2015 Feb;
71(3):341-55.
PMID: 25673568
Purpose: Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure exists for other statins. Methods: Plasma exposure following...
8.
Husted S, Storey R, Bliden K, Tantry U, Hoimark L, Butler K, et al.
Clin Pharmacokinet
. 2012 Apr;
51(6):397-409.
PMID: 22515556
Background And Objectives: Ticagrelor, the first reversibly binding oral P2Y(12) receptor antagonist, improves outcomes in patients with acute coronary syndromes (ACS) compared with clopidogrel. In the ONSET-OFFSET study (parallel group...
9.
Bliden K, Tantry U, Storey R, Jeong Y, Gesheff M, Wei C, et al.
Am Heart J
. 2011 Jul;
162(1):160-5.
PMID: 21742103
Objectives: The objective of the study was to determine the prevalence of high on-treatment platelet reactivity (HPR) in coronary artery disease patients enrolled in the ONSET/OFFSET and RESPOND studies. Background:...
10.
Tantry U, Bliden K, Wei C, Storey R, Armstrong M, Butler K, et al.
Circ Cardiovasc Genet
. 2010 Nov;
3(6):556-66.
PMID: 21079055
Background: The influence of cytochrome P450 (CYP) 2C19 genotype on platelet function in patients treated with ticagrelor versus clopidogrel is unknown. Methods And Results: CYP2C19 (*1, *2, *3, *4, *5,...